Pressreleases

19 Dec 2016

Unique investment by Swedish pharmaceutical company

ABIGO Medical is the only company manufacturing advanced wound care products in Sweden. The company has substantial international presence with strong growth. Products are sold to 70 countries, with turnover of approximately 300 MSEK. Now ABIGO gears up further. By investing 30 MSEK in their production facility, they expect an annual production increase by 15-20 %.

ABIGO Medical’s strictly organic growth strategy and their self-financed R&D-operation has resulted in a great international success, with an ever increasing demand. In order to meet this, ABIGO has invested heavily in the expansion of the production facility in Askersund. While many pharmaceutical companies nowadays choose to move production abroad, ABIGO sees the advantages of maintaining both headquarters, R&D and production in Sweden.

“In recent years, we’ve seen a steady growth and the trend seems to continue. At the end of 2016, we expect to be approximately 60 employees”, says Fredrik Stenbäcker, Plant Manager at ABIGO’s production facility in Askersund, recently expanded to a total of 5000 sqm.

Swedish innovation in the fight against antibiotic resistance

In 1989, the brothers and entrepreneurs Jan G. Smith and Leif Smith founded ABIGO Medical AB, with a focus on delivering innovative methods of infection control and to reduce the use of antibiotics. The infection preventive dressing Sorbact® eventually became the flagship of the business and is also the main reason behind the new investment.

“Sorbact® offers fantastic opportunities, particularly in view of the global challenges of infections and antimicrobial resistance”, Jan G. Smith, CEO at ABIGO Medical explains.

Sorbact® prevents and treats infections by binding bacteria to the surface of the dressing, without releasing any chemical agents into the wound. The bacteria are removed when the dressing is changed. By preventing infections, Sorbact® also helps to reduce the need of antibiotics, hence lessening the risk of spreading multi-resistant bacteria. The Sorbact® method is an innovation, based on Swedish research. In a recently published international and controlled clinical study1, Sorbact® was compared to a standard dressing among women undergoing cesarean section. The result confirmed the efficacy and cost-effectiveness of Sorbact®. Excellent results in international studies combined with many years of clinical experience, has led to a sharp increase in the use of the Sorbact® For example, all French University Hospitals use Sorbact®.

Financially independent

ABIGO Medical is an entrepreneurial company with financial stamina and long-term perspective as core values. The company has also reinvested its profits in the business over the years.

“To be financially independent and not having to rely on venture capital is one of our incentives,” says Leif Smith, President at ABIGO Group.

Leif owns and actively manages the company together with his brother Jan.

“We do not like the quarterly economy hysteria. It’s neither good for business nor for Sweden.”“We have seen many good products and innovations succumbing to the venture capital’s lack of patience”, Jan adds.

According to the brothers, the fight against multi-resistant bacteria is the most exciting area and this is where ABIGO has a unique competence. The prevention of infections in itself is an incredibly large area and there are a multitude of applications for the innovations owned by ABIGO.

“We have barely scratched the surface,” Leif Smith says.

For more information,
contact Björn Larsson, bjorn.larsson@abigo.se, phone: +46 766 201 725

1. Stanirowski PJ et al. Surgical Infections 2016; [ahead of print]. DOI: 10.1089/sur.2015.223. The full study is available here: http://online.liebertpub.com/doi/pdfplus/10.1089/sur.2015.223

Click her for:

Images

About Sorbact®

About ABIGO Medical

 

28 Jun 2016

ABIGO Medical expands the Sorbact® range of infection preventive dressings with the Foam Gentle Border dressing

The new Sorbact® Foam Gentle Border dressing further extends the use of Sorbact® Technology with an all-in-one dressing with gentle silicone adhesive border, especially suitable for patients with sensitive or vulnerable skin. The Sorbact® range of microbial binding dressings help preventing infections as well as managing already infected and hard-to-heal wounds. Infected wounds mean longer healing times, leading to unnecessary suffering for the patient and increased costs for the community.

Sorbact® Foam Gentle Border is an atraumatic all-in-one dressing that reduces bioburden in a wide range of wounds. It consists of a green Sorbact® wound contact layer, polyurethane foam, soft silicone adhesive borders and a vapor permeable polyurethane backing film. Sorbact® Foam Gentle Border is intended for use in management of clean, colonized, contaminated or infected wounds with moderate exudate levels, such as surgical wounds, traumatic wounds, pressure ulcers, diabetic ulcers and foot and leg ulcers.

The skin-friendly soft silicone adhesive borders make Sorbact® Foam Gentle Border dressing especially suitable in patients with sensitive or vulnerable skin, i.e. elderly patients, patients who are sensitive to common plasters or surgical tape, patients with thin skin due to long-term use of systemic corticosteroids, and children who are experiencing pain when removing a patch.

Sorbact® Foam Gentle Border is based on the Sorbact® Technology with a wound contact surface more attractive for microorganisms than the wound bed. The microorganisms bind irreversibly to Sorbact®, and are removed at dressing change. Sorbact® Foam Gentle Border can be used prophylactically to prevent infections in different types of wounds and is available in three different sizes.

– Adding the Foam Gentle Border dressing to the Sorbact® product range is a response to customer and patient needs, says Mattias Andrup, Medical Affairs Director at ABIGO Medical. We are delighted to be able to offer this gentle all-in-one dressing combined with the Sorbact® Technology advantage.

Sorbact® Foam Gentle Border was launched in conjunction with the 26th conference of European Wound Management Association, EWMA 2016, 11–13 May in Bremen, Germany.

Contact Björn Larsson, Marketing Communication Director, bjorn.larsson@abigo.se, +46 31 36 14 887

More about Sorbact®
Common wound microorganisms bind to Sorbact®, such as Staphylococcus aureus, Streptococcus species, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, and including MRSA¹ bacteria. No mechanisms of resistance to Sorbact® have been described. Sorbact® does not contain or release toxic agents and can be used with children and during pregnancy. Sorbact® is available in a comprehensive range of dressing types and sizes and, through our partners and distributors, used in in more than 65 countries. For more information on Sorbact® please visit http://www.abigo.com/products/wound-fungus/sorbact/

About ABIGO Medical
ABIGO Medical is a Swedish entrepreneurial pharmaceutical company that owns, develops, manufactures and markets pharmaceuticals and medical devices. ABIGO Medical has a wide range of non-prescription and prescription drugs, as well as a range of medical products in advanced wound management and ear, nose and throat (ENT) treatment, as well as food for special medical purposes. The company was founded in 1989 by the current owners, brothers Jan G. Smith and Leif Smith, both still actively involved in the ABIGO management. ABIGO’s products are sold and used in over 65 countries, through its own sales organizations and partners. Consolidated turnover for 2015/2016 will be approximately SEK 275 million and continued growth is expected, which is reinvested in research and development. To meet the surge in demand, including Sorbact®, more than 40 million SEK is invested to multi-double capacity at the company’s production plant in Askersund.

Sorbact® is a registered trademark of ABIGO Medical AB.

References:
Rönner AC, Curtin J, Karami N, and Rönner U. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings. J Wound Care 2014; 23(10):484, 486-488.